• Subjects must volunteer to participate in the study, signed informed consent, and were able to comply with the program requirements of visits and related procedures.

• Age and gender: \>18 years old and≤75 years old, both men and women.

• All subjects must have Hepatocellular Carcinoma confirmed by pathological or clinical diagnosis.

• Subjects are not suitable for radical resection or radical ablative therapy.

• BCLC B based on Barcelona Clinic Liver Cancer staging system, and the lesions in the liver exceed up to 7 criteria, the number of tumors + the maximum diameter of tumors \> 7.

• Patients with viable and measurable target lesion per mRECIST.

• Patients who are expected to live more than 3 months.

• ECOG PS 0-1.

• Child-Pugh class A.

⁃ Patients with laboratory values that meet the following criteria:

∙ Hemoglobin≥90 g/L;

‣ Neutrophile granulocytes≥1.5×109/L;

‣ Platelet count≥75×109/L;

‣ Albumin≥30 g/L;

‣ Total serum bilirubin ≤ 2 times upper limits of normal;

‣ AST and ALT ≤ 5 times upper limits of normal;

‣ Serum creatinine ≤ 1.5 times upper limits of normal;

‣ Alkaline phosphatase ≤ 5 times upper limits of normal;

‣ Prothrombin time or international normalized ratio ≤ 1.5 times upper limits of normal, activated partial thromboplastin time (APTT) ≤ 1.5×ULN;